---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-24-000143"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:49:57.891877+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics Q2 net loss $55.9M; cash $438.1M; bexotegrast trials on track

## Summary
- Net loss $55.9M vs $41.2M prior year; R&D expense up to $45.6M driven by BEACON-IPF trial.
- Cash, equivalents & short-term investments $438.1M as of June 30, 2024.
- Phase 2a PET imaging trial showed reduced total lung collagen and improved FVC in IPF patients on bexotegrast.
- BEACON-IPF Phase 2b enrollment on track for Q1 2025 completion; data anticipated mid-2026.
- Steve Krognes, former Denali Therapeutics CFO, appointed to Board of Directors.

## SEC filing metadata
- accession: 0001746473-24-000143
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000143/0001746473-24-000143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000143/plrx-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-24-000143
- JSON: https://secwatch.observer/filing/0001746473-24-000143.json
- Plain text: https://secwatch.observer/filing/0001746473-24-000143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.